Abstract
During the past 10 years an extensive literature has been generated concerning the risks and benefits of hormonal replacement therapy in post-menopausal women. Although some of the questions have been answered during this period, controversy about the risk of breast cancer continues. This paper attempts to evaluate the risk of breast cancer in the light of epidemiological, experimental and histological findings. An interpretation of the available data and practical therapeutic recommendations are given. It is concluded that no change in the currently recommended schedule of combined sequential estrogen progestin therapy is necessary at this stage.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
